OccamzRazor
OccamzRazor is focused on innovative drug discovery utilizing digital science to understand and cure brain aging, particularly targeting Parkinson’s disease. The company employs advanced technologies to analyze data from various sources, aiming to improve drug discovery outcomes. Their unique approach combines machine learning with biological techniques, allowing for the extraction of valuable insights from both structured and unstructured data. This positions OccamzRazor as a leader in the field of drug development, with a strong emphasis on addressing complex neurological conditions.
OccamzRazor
OccamzRazor is focused on innovative drug discovery utilizing digital science to understand and cure brain aging, particularly targeting Parkinson’s disease. The company employs advanced technologies to analyze data from various sources, aiming to improve drug discovery outcomes. Their unique approach combines machine learning with biological techniques, allowing for the extraction of valuable insights from both structured and unstructured data. This positions OccamzRazor as a leader in the field of drug development, with a strong emphasis on addressing complex neurological conditions.
TL;DR
Focus: AI/ML-driven drug discovery for brain‑aging diseases, starting with Parkinson’s
Founded: 2015
Headquarters: New York City (Johnson & Johnson Innovation JLABS resident)
Latest disclosed round: Series A (Mar 2022), ~ $6.1M (led by Jeff Dean)
Tech / products: RazorBrain, RazorLink, RazorPanorama (ML, graph representation learning, NLP)
Company Overview
Problem Domain
Drug discovery for brain‑aging and neurodegenerative diseases, starting with Parkinson’s disease.
Founded
2015
Industry
Biotechnology
Tech Stack
Funding Track Record
6100000
Company announced approximately $6.1M financing in March 2022 to launch AI-enabled discovery pipeline and advance Parkinson’s preclinical development.
Investor Signal
“Led by Jeff Dean; investors include Lauder Partners, re.Mind Capital, Valor Equity Partners, Techammer (Jeff Hammerback), Phil Libin, and others”